Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

P. Bramanti, E. Sessa, C. Rifici, G. D'Aleo, D. Floridia, P. Di Bella, F. Lublin

Research output: Contribution to journalArticlepeer-review

Abstract

Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

Original languageEnglish
Pages (from-to)1720-1723
Number of pages4
JournalNeurology
Volume51
Issue number6
Publication statusPublished - 1998

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b'. Together they form a unique fingerprint.

Cite this